HLS Therapeutics - HLS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: C$10.28
  • Forecasted Upside: 157.08%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$4.00
▲ +0.02 (0.50%)

This chart shows the closing price for HLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HLS Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLS

Analyst Price Target is C$10.28
▲ +157.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for HLS Therapeutics in the last 3 months. The average price target is C$10.28, with a high forecast of C$17.50 and a low forecast of C$4.35. The average price target represents a 157.08% upside from the last price of C$4.00.

This chart shows the closing price for HLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in HLS Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/22/2024Stifel NicolausLower TargetC$5.00 ➝ C$4.35
2/6/2024Clarus SecuritiesReiterated RatingBuy
11/10/2023Stifel NicolausDowngradeBuy ➝ HoldC$12.25 ➝ C$5.00
11/9/2023Stifel CanadaDowngradeBuy ➝ Hold
9/19/2023Stifel NicolausLower TargetBuyC$15.00 ➝ C$12.25
8/11/2023Stifel NicolausLower TargetC$18.00 ➝ C$15.00
7/28/2023Raymond JamesLower TargetMarket PerformC$10.00 ➝ C$9.00
3/17/2023Raymond JamesDowngradeOutperform ➝ Market PerformC$24.00 ➝ C$15.00
3/17/2023Canaccord Genuity GroupLower TargetC$21.75 ➝ C$17.50
3/17/2023Stifel NicolausLower TargetC$26.00 ➝ C$18.00
11/11/2022Stifel NicolausLower TargetC$32.00 ➝ C$26.00
8/25/2022Raymond JamesLower TargetOutperformC$28.00 ➝ C$24.00
8/12/2022Stifel NicolausLower TargetC$36.00 ➝ C$32.00
7/26/2022Bloom BurtonReiterated RatingBuyC$22.00
7/25/2022Clarus SecuritiesReiterated RatingBuyC$26.50
5/9/2022Raymond JamesSet TargetOutperformC$28.00
5/3/2022Raymond JamesBoost TargetOutperformC$26.00 ➝ C$28.00
4/27/2022Raymond JamesSet TargetOutperformC$26.00
4/27/2022Clarus SecuritiesReiterated RatingBuyC$26.50
3/21/2022Clarus SecuritiesReiterated RatingBuyC$33.00
3/21/2022Raymond JamesSet TargetOutperformC$26.00
3/18/2022Canaccord Genuity GroupLower TargetC$30.75 ➝ C$30.50
3/15/2022Raymond JamesSet TargetOutperformC$26.00
12/16/2021Raymond JamesSet TargetOutperformC$26.00
12/16/2021Raymond JamesReiterated RatingBuyC$26.00
12/6/2021Stifel NicolausReiterated RatingBuyC$36.00
11/5/2021Raymond JamesReiterated RatingBuyC$25.00
11/5/2021Raymond JamesSet TargetOutperformC$26.00
11/5/2021Clarus SecuritiesReiterated RatingBuyC$32.00
10/28/2021Raymond JamesSet TargetOutperformC$26.00
10/28/2021Raymond JamesReiterated RatingOutperformC$26.00
8/17/2021Raymond JamesUpgradeOutperformC$26.00
8/6/2021Raymond JamesDowngradeMarket PerformC$28.00 ➝ C$24.00
8/5/2021Bloom BurtonReiterated RatingBuy
5/10/2021Raymond JamesBoost TargetOutperformC$28.00
5/10/2021Raymond JamesSet TargetOutperformC$28.00
5/4/2021Raymond JamesSet TargetOutperformC$28.00
5/4/2021Raymond JamesReiterated RatingOutperformC$28.00
3/30/2021Raymond JamesBoost TargetOutperformC$28.00
3/30/2021Raymond JamesSet TargetOutperformC$28.00
3/24/2021Raymond JamesBoost TargetOutperformC$28.00
3/22/2021Raymond JamesSet TargetOutperformC$27.00
3/16/2021Raymond JamesReiterated RatingOutperformC$27.00
3/16/2021Raymond JamesSet TargetOutperformC$27.00
2/18/2021Raymond JamesReiterated RatingOutperformC$27.00
2/4/2021Raymond JamesSet TargetOutperformC$27.00
2/3/2021Raymond JamesReiterated RatingOutperformC$27.00
1/29/2021Raymond JamesSet TargetOutperformC$27.00
1/22/2021Raymond JamesInitiated CoverageOutperformC$27.00
7/21/2020Bloom BurtonUpgradeAccumulate ➝ Buy
3/31/2020Bloom BurtonDowngradeBuy ➝ Accumulate
1/2/2020Clarus SecuritiesReiterated RatingSpeculative Buy ➝ Buy
11/21/2019Clarus SecuritiesReiterated RatingSpeculative Buy
10/4/2019Bloom BurtonUpgradeHold ➝ Buy
8/9/2019Bloom BurtonDowngradeBuy ➝ Hold
3/22/2019Bloom BurtonReiterated RatingBuy
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/2/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/30/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/28/2024

Current Sentiment

  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

HLS Therapeutics logo
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Read More

Today's Range

Now: C$4.00
Low: C$3.97
High: C$4.03

50 Day Range

MA: C$4.01
Low: C$3.64
High: C$4.28

52 Week Range

Now: C$4.00
Low: C$3.34
High: C$9.50

Volume

2,656 shs

Average Volume

4,552 shs

Market Capitalization

C$128.28 million

P/E Ratio

N/A

Dividend Yield

5.03%

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of HLS Therapeutics?

The following equities research analysts have issued stock ratings on HLS Therapeutics in the last year: Canaccord Genuity Group Inc., Clarus Securities, Raymond James, Stifel Canada, and Stifel Nicolaus.
View the latest analyst ratings for HLS.

What is the current price target for HLS Therapeutics?

3 Wall Street analysts have set twelve-month price targets for HLS Therapeutics in the last year. Their average twelve-month price target is C$10.28, suggesting a possible upside of 157.1%. Canaccord Genuity Group Inc. has the highest price target set, predicting HLS will reach C$17.50 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of C$4.35 for HLS Therapeutics in the next year.
View the latest price targets for HLS.

What is the current consensus analyst rating for HLS Therapeutics?

HLS Therapeutics currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HLS, but not buy more shares or sell existing shares.
View the latest ratings for HLS.

What other companies compete with HLS Therapeutics?

How do I contact HLS Therapeutics' investor relations team?

HLS Therapeutics' physical mailing address is 10 Carlson Court, Suite 701, Etobicoke, ON M9W 6L2, Canada. The company's listed phone number is 647-495-9000. The official website for HLS Therapeutics is www.hlstherapeutics.com. Learn More about contacing HLS Therapeutics investor relations.